Novartis Investigative Site

Evansville, Indiana 47715

0 studies enrolling now · 21 studies all time

What they study most

Ankylosing Spondylitis, Asthma, Atherosclerosis, Breast Cancer, Chronic Inducible Urticaria, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD), Chronic Plaque-type Psoriasis, Chronic Spontaneous Urticaria, Heart Failure With Reduced Ejection Fraction, Hypertension, Moderate to Severe Allergic Asthma

Studies at this site

• A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines — Completed
• Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer — Completed
• Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab — Stopped early
• Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines — Stopped early
• A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines — Completed
• Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis — Completed
• A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients — Completed
• Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU — Completed
• Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year — Completed
• A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis — Completed
• Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma — Completed
• Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201 — Stopped early
• A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation — Completed
• Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients — Completed
• AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis — Completed
• NVA237 BID Versus Placebo Twelve-week Efficacy Study — Completed
• 8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension — Completed
• A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma — Completed